Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
H
Hahn, Erik
Pfizer, Inc.
(
S-105
)
POPULATION PHARMACOKINETIC (POPPK) MODELING OF IRINOTECAN AND SN38 IN PARTICIPANTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN PHASE 2 AND 3 STUDIES: A SEQUENTIAL PARENT-METABOLITE MODEL
Erik Hahn
Favorite
Haid, Robin
Bayer AG / Vividion Inc.
(
M-058
)
Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection
Robin Haid
Favorite
Hai, Min
The Ohio State University
(
S-102
)
Mathematical Modeling to Optimize Receptor Occupancy Assay Development for Isatuximab
Min Hai
Favorite
Hajjawi, Malek
Indiana University
(
S-101
)
A Population Pharmacokinetic Approach to Prospectively Assess Vancomycin Pharmacokinetics in Adult Jordanian Patients: a Step towards Personalized Dosing
Malek Hajjawi
Favorite
Hallow, Melissa
Cardiorenal QSP, LLC
(
T-052
)
Application of Neural ODEs for Agnostic Inference of Feedback Mechanism Structure in QSP Models
Melissa Hallow
Favorite
(
T-053
)
QSP Modeling of Potassium Regulation in Rare and Complex Cardiorenal Disorders
Melissa Hallow
Favorite
Hamada, Izumi
Bristol Myers Squibb
(
S-047
)
Population Pharmacokinetics and Exposure-Response Analysis of Nivolumab in Combination with Ipilimumab in Participants with First-Line Unresectable or Advanced Hepatocellular Carcinoma to Support Benefit-Risk Assessment
Izumi Hamada
Favorite
Hayato, Seiichi
Eisai
(
T-074
)
Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Patients with Solid Tumors
Seiichi Hayato
Favorite
Hegde, Renuka
Bristol Myers Squibb
(
S-031
)
Case Study: Integrating ADPPK CDISC Standards into Pharmacometric Programming and Analysis Workflows
Renuka Hegde
Favorite
(
S-032
)
Exploring Python to Prepare CDISC-Compliant Analysis Datasets for Pharmacometric Analyses
Renuka Hegde
Favorite
Henscheid, Nick
Critical Path Institute
(
M-083
)
Disease progression simulation via generative AI: assessing the credibility of a conditional longitudinal autoencoder via a case study in Alzheimer’s Disease
Nick Henscheid
Favorite
Her, Lucy
Eli Lilly and Company
(
T-010
)
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies
Lucy Her
Favorite
Herron, Cody
Pfizer
(
T-066
)
QSP Model of RSV Viral Dynamics in Healthy Adult and Pediatric Patient Populations
Cody Herron
Favorite
Hosawi, Anhar
University of Cincinnati / Cincinnati Children's
(
S-110
)
Simulating Relative Infant Hydroxyurea Dose Through Breastfeeding Using a Semi-Mechanistic Population PK Model
Anhar Hosawi
Favorite
Hsieh, Po-I
United Therapeutics Corporation
(
T-097
)
Development of a Combined Deposition–Physiologically Based Pharmacokinetic Model for Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis
Po-I Hsieh
Favorite
Huang, Weize
Genentech
(
T-047
)
Development of Dosing Selection Strategy for Brain Penetrants
Weize Huang
Favorite
Hu, Chuanpu
Bristol Myers Squibb
(
S-042
)
Full covariate model construction, usage, and reduction in population pharmacokinetics
Chuanpu Hu
Favorite
Hughes, Jasmine
InsightRX
(
T-068
)
Model selection for precision dosing: Comparison of Machine Learning and Evidence-plus-Expertise Algorithms
Jasmine Hughes
Favorite
Huisman, Marc
Amsterdam UMC, Amsterdam, The Netherlands
(
T-045
)
89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism
Marc Huisman
Favorite
Hunter, Asama
Teva Branded Pharmaceuticals LLC
(
S-090
)
An Empirical Drug Autoinduction Model to Characterize the Population Pharmacokinetics of TEV-56286 (Emrusolmin) in Healthy Participants and Patients
Asama Hunter
Favorite
Hurh, Eunju
(
M-095
)
Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma
Eunju Hurh
Favorite
Hu, Shihao
Janssen Research & Development
(
S-006
)
Population Pharmacokinetics and Exposure-Response Analysis for TAR-200, an Intravesical Drug Delivery System for Bladder Cancer Treatment
Shihao Hu
Favorite
